Find your path to Clare
130 people in our graph can introduce you to Clare.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Nicholas Talarico to introduce you to Clare
You →Nicholas · together at StealthCo (2024–2026) →Clare
Ask Jamie Chen to introduce you to Clare
You →Jamie · together at RQ Biotechnology Ltd. →Clare
Ask Sam Okafor to introduce you to Clare
You →Sam · together at cumulus-neuroscience →Clare
Sign up to find every way you can get introduced to Clare
- Your email: the people you already email who know Clare
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Clare
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
Head of LifeArc Ventures and a member of the LifeArc Leadership Team, responsible for the venture and LP investment portfolio across life sciences. She previously led Corporate Development at Syncona Investment Management and spent over 15 years in biotech and healthcare finance at Nomura, Numis Securities and Peel Hunt, having earlier worked as a physiotherapist in Canada.
Experience
- LifeArc VenturesManaging Partner, Head of LifeArc Venturescurrent2020 — presentGreater London, England, United Kingdom
- BioIndustry AssociationBoard Member, Chair of Audit Committeecurrent2018 — presentLondon Area, United Kingdom
- RQ Biotechnology Ltd.Chaircurrent2021 — presentGreater London, England, United Kingdom
- Stealth Mode UK Biotech CompanyDirectorcurrent2024 — presentCambridge, England, United Kingdom
- StealthCoBoard Observercurrent2023 — presentLondon, UK
- Closed Loop MedicineDirectorcurrent2021 — presentGreater London, England, United Kingdom
- Cumulus NeuroscienceDirector2023 — 2025Belfast, Northern Ireland, United Kingdom
- Avvinity Therapeutics LimitedDirector2021 — 2024Greater London, England, United Kingdom
- Stevenage Bioscience CatalystBoard Member, Chair of Audit Committee2019 — 2023Stevenage, England, United Kingdom
- DJS Antibodies [Acquired by Abbvie Oct 22]Director2021 — 2022Oxford, England, United Kingdom
- DUCENTIS BIOTHERAPEUTICS LTD. [Acquired by Arcutis Biotherapeutics Sept 2022]Director2021 — 2022Oxford, England, United Kingdom
- Syncona LimitedHead of Corporate Development2018 — 2020London Area, United Kingdom
- Numis SecuritiesManaging Director, Healthcare & Life Sciences, Investment Banking2015 — 2018London Area, United Kingdom
- Peel Hunt LLPDirector, Corporate Investment Banking, Healthcare and Life Science2014 — 2015London Area, United Kingdom
- Nomura Code Securities, Nomura InternationalDirector, Corporate Finance2005 — 2013London Area, United Kingdom
- Nomura Code Securities, Nomura InternationalPartner, Corporate Finance2004 — 2005London Area, United Kingdom
- Dalhousie University Sports Centre, PhysiotherapyPhysiotherapist1996 — 2000Canada
Skills & more
+9 more
Due DiligenceVenture CapitalValuationEmerging MarketsEquity Capital MarketsRestructuringLBOFinancial StructuringFinancial ModelingFrom Clare's professional profile.
Colleagues at LifeArc Ventures
Frequently asked questions
- Who is Clare Terlouw?
- Head of LifeArc Ventures and a member of the LifeArc Leadership Team, responsible for the venture and LP investment portfolio across life sciences. She previously led Corporate Development at Syncona Investment Management and spent over 15 years in biotech and healthcare finance at Nomura, Numis Securities and Peel Hunt, having earlier worked as a physiotherapist in Canada.
- Where does Clare Terlouw work?
- Clare Terlouw is Managing Partner at LifeArc Ventures.
- Where did Clare Terlouw go to school?
- Clare Terlouw studied at Queen's University (BSc. P.T, Physiotherapy); Saint Mary's University (MBA, Finance).
Same school
Also attended Queen's University470
+ 464 more
Also attended Saint Mary's University27
+ 21 more
Shared employers
Also worked at StealthCo1
Also worked at Closed Loop Medicine5
Also worked at Stevenage Bioscience Catalyst1
Also worked at Syncona Limited18
+ 12 more










































